Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Oncología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 1
ClinicalTrials.gov
A Phase 1 Study to Compare Bempegaldesleukin Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (mRCC) (PIVOT IO 011)
INTERVENTIONAL
Inicio: 11 de sept de 2020
ID: NCT04540705
Por invitación
Fase 3
ClinicalTrials.gov
Open-label, Safety Extension Study for Subjects With HR+, HER2-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer OVELIA Study
INTERVENTIONAL
Inicio: 28 de dic de 2022
ID: NCT05645536
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
INTERVENTIONAL
Inicio: 31 de oct de 2018
ID: NCT03668119
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL
INTERVENTIONAL
Inicio: 4 de ene de 2021
ID: NCT04521231
Completado
Fase 3
ClinicalTrials.gov
A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
INTERVENTIONAL
Inicio: 8 de nov de 2011
ID: NCT01358877
Completado
Fase 3
ClinicalTrials.gov
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
INTERVENTIONAL
Inicio: 1 de sept de 2008
ID: NCT00686959
Reclutando
ClinicalTrials.gov
A Multicentre Study Assessing Ophthalmic Safety in Patients With Breast Cancer
OBSERVATIONAL
Inicio: 4 de mar de 2025
ID: NCT06767462
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
INTERVENTIONAL
Inicio: 19 de jul de 2010
ID: NCT01137682
Suspendido
Fase 3
ClinicalTrials.gov
MULTIMODALITY TREATMENT STRATEGY FOR STAGE III BREAST CANCER
INTERVENTIONAL
Inicio: 1 de oct de 1995
ID: NCT00002696
Completado
ClinicalTrials.gov
Avastin in First Line Metastatic or Recurrent Breast Cancer. Retrospective Phase IV Study
OBSERVATIONAL
Inicio: 1 de ene de 2010
ID: NCT01215123
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
INTERVENTIONAL
Inicio: 2 de mar de 2006
ID: NCT00338286
Completado
ClinicalTrials.gov
An Observational Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina
OBSERVATIONAL
Inicio: 9 de feb de 2018
ID: NCT03330886
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)
INTERVENTIONAL
Inicio: 16 de nov de 2023
ID: NCT05920356
Terminado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
INTERVENTIONAL
Inicio: 1 de jun de 2008
ID: NCT00667810
Completado
Fase 3
ClinicalTrials.gov
A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
INTERVENTIONAL
Inicio: 6 de ene de 2018
ID: NCT03337724
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
INTERVENTIONAL
Inicio: 23 de jun de 2015
ID: NCT02425891
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
INTERVENTIONAL
Inicio: 30 de jun de 2015
ID: NCT02467270
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)
INTERVENTIONAL
Inicio: 13 de oct de 2015
ID: NCT02538666
Completado
Fase 2
ClinicalTrials.gov
Phase II Trial of Trimetrexate (Neutrexin), 5-Fluorouracil and Leucovorin in Metastatic Colorectal Cancer
INTERVENTIONAL
Inicio: 1 de dic de 1997
ID: NCT00003446
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)
INTERVENTIONAL
Inicio: 22 de mar de 2016
ID: NCT02632409
Anterior
1
...
53
54
55
...
434
Siguiente
Filtros